Home PC News Filtricine Initiates the First Human Clinical Study of Cancer Management Using Its...

Filtricine Initiates the First Human Clinical Study of Cancer Management Using Its Proprietary Medical Food For Targeted Nutrient Deprivation (TND) Technology

SANTA CLARA, Calif.–(BUSINESS WIRE)–July 8, 2020–

Filtricine at this time introduced the beginning of its first human medical research amongst prostate most cancers sufferers. The research, led by and performed on the Stanford University School of Medicine, seeks to ascertain the protection, palatability, and tolerability of a food regimen consisting solely of Tality™ artificial meal substitute. Tality™ is specifically designed for the dietary administration of most cancers sufferers utilizing Filtricine’s patent-pending TND Medical Food know-how with the objectives of slicing off the diet provide to most cancers cells with out harming wholesome cells.

“Our pre-clinical research has shown that Tality™ provides complete, balanced nutrition, while restricting nutritional support to cancer cells. This clinical trial is an important step toward enabling Tality™ to provide cancer patients with safe and effective ways to manage their health,” stated Filtricine CEO Xiyan Li, Ph.D. “Tality™ nurtures the body with the essential vitamins, minerals and proteins. It also helps maintain metabolic and immune health. We hope to firmly establish that cancer patients can consume Tality™ exclusively for 4 weeks as a sole source of nutrition to help manage their health during treatment.”

The final aim of Filtricine is to supply business medical meals merchandise to the oncology marketplace for secure and efficient most cancers administration. “We are currently seeking capital to expedite our path toward multi-site clinical trials,” stated Dr. Li.

VB Transform 2020 Online – July 15-17. Join main AI executives: Register for the free livestream.

“Growing science points to the potential power of food and nutrition to help manage cancer and reduce side effects from conventional cancer therapies,” stated Dr. Dariush Mozaffarian, a doctor, public well being skilled, and member of Filtricine’s Scientific Advisory Board. He is the Jean Mayer Professor of Nutrition and Medicine on the Friedman School of Nutrition Science and Policy at Tufts University. “Innovative approaches are needed to help the nearly 2 million Americans who are newly diagnosed with cancer each year in the United States, and the many millions more around the world.”

If you wish to study extra, please go to https://www.clinicaltrials.gov/ct2/show/NCT04389918


Filtricine is a clinical-stage biotech firm that goals to ascertain its patent-pending focused nutrient deprivation (TND) platform to remodel most cancers administration and well being enchancment. TND know-how was developed to successfully minimize off the availability of vitamins most cancers cells require for progress, whereas non-cancerous cells safely obtain all the mandatory vitamins wanted to stay wholesome. We consider that TND know-how can profit many sufferers residing with most cancers. For extra info, please go to www.filtricine.com.

Xiyan Li
(650) 450-7397
[email protected]

Diane Lee
(310) 806-2066
[email protected]

Most Popular

Recent Comments